Androgenic Alopecia, (Male Pattern Baldness) is not indicator of prostate cancer.

Androgenic Alopecia has been thought to may be associated with possible connection to prostate growth (bph and prostate cancer. This correlation is derived from the basis of hair loss research that was discovered during the finasteride (Propecia) discovery and research years, and the role of dihydrotestosterone (DHT) to hair loss.

Finasteride blocks the receptor for DHT and was found to help benign prostate hyperplasia, and as a side effect keep patients hair.

A new study published in December 2010 from  The Department of Epidemiology, Biostatistics and HTA, at Radboud University Nijmegen Medical Centre in The Netherlands found no positive correlation in a patients androgenic alopecia and their risk of hair loss.

Because BPH does not progress into Prostate cancer the study seems to confirm any questions of androgenic alopecia maybe being related to Prostate Cancer, but that is not the case.

The study based on the premise that androgens are assumed to play a central role in the pathophysiology of both prostate cancer (PC) and androgenic alopecia (AA). A correlation between the two phenotypes may be relevant for identification of men at high risk of PC.

The researchers evaluated the association between AA at different ages and PC in a large case-control study.

The case group comprised 938 PC patients recruited from a population-based cancer registry. The controls (n = 2160) were a random sample of the male general population. All subjects completed a questionnaire on risk factors for cancer, including questions on hair pattern at different ages using an adapted version of the Hamilton-Norwood scale, race and family history of PC. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable logistic regression.

The researchers found that baldness at early age appeared to be associated with a lower risk of PC (baldness at age 20: OR = 0.86; 95% CI 0.69-1.07 and baldness at age 40: OR = 0.81; 95% CI 0.70-0.96). Baldness at completion of the questionnaire was not associated with PC: OR = 1.10; 95% CI 0.89-1.34. An isolated ‘frontal baldness’ or ‘vertex baldness’ pattern was not significantly associated with PC at any age. Presence of a combined ‘frontal and vertex’ baldness pattern at age 40 was associated with a decreased risk of PC (OR = 0.62; 95% CI 0.45-0.86). There were no significant associations between AA and aggressive PC.

The research team  did not find consistent positive associations between AA at different ages and PC. Link to study info here

Most surprising to us and the researchers was that, if anything, baldness at early age is inversely related to Prostate Cancer in this study.

So there you have it: Androgenic alopecia (male pattern baldness) is not useful as an indicator of men at high risk of Prostate Cancer.

Share on Facebook

PRWEB Business Release

Increased World Wide Demand For New Zenagen Hair Loss Product Line Causes Company To Revise Outlook And Distribution For 2010. New Hair Loss Technology and Formulation Techniques Have Increased Industry Demand.

Miami, FL (PRWEB) June 22, 2010 — Nutraceutical Research Innovations, LLC (NRI) announced increased production of the patent-pending Zenagen hair loss product line, due to increased world-wide demand the hair care products. The Miami based nutraceutical company introduced Zenagen hair loss shampoo at the International Beauty and Barber Show, Miami in August 2009. The company focuses on nutraceutical formulation and extraction process and developed the formulation for the patent-pending Zenagen hair care line of hair loss products.

To Order Zenagen During the Exclusive Offer Event Click Here To Go To The Hair Loss Shampoo Website.

The Zenagen hair loss line has rapidly expanded its distribution and international presence and has been expanding retail availability through exclusive distribution agreements.

The hair loss industry has experienced rapid development over the last 20 years with the introduction of blockbuster FDA approved products finasteride (Propecia) and Minoxidil (Rogaine). The billion dollar hair loss market has shown rapid growth. Hair loss affects over 80 million people in the US alone, with some studies showing the prevalence of mid-frontal hair loss increases with age and affects 57% of women and 73.5% of men aged 80 and over.

The most common cause of alopecia is known as androgenic alopecia, and is thought to be caused by the hormone dihydrotestosterone (DHT) a derivative of testosterone. DHT initiates a process of follicular miniaturization. Through the process of follicular miniaturization, hair shaft width is progressively decreased until scalp hair resembles fragile vellus hair or “peach fuzz” or else becomes non-existent.

NRI has recently expanded their focus of hair loss solutions including genetic research and gene therapy and expects to conclude a 3rd party phase 1 research study in early 2011.

Click Here To Return to Hair Loss Blog

Click Here To Visit Zenagen Hair Loss Products Website

Share on Facebook